64Cu-based radiopharmaceuticals in molecular imaging

50Citations
Citations of this article
102Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Copper-64 (T1/2 = 12.7 hours; β+: 19%, β-: 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide.

Author supplied keywords

Cite

CITATION STYLE

APA

Zhou, Y., Li, J., Xu, X., Zhao, M., Zhang, B., Deng, S., & Wu, Y. (2019). 64Cu-based radiopharmaceuticals in molecular imaging. Technology in Cancer Research and Treatment. SAGE Publications Inc. https://doi.org/10.1177/1533033819830758

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free